Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems

The subdued market reaction suggests that Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earnings.

See our latest analysis for Chengdu Easton Biopharmaceuticals

The Impact Of Unusual Items On Profit

For anyone who wants to understand Chengdu Easton Biopharmaceuticals' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥65m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Chengdu Easton Biopharmaceuticals had a rather significant contribution from unusual items relative to its profit to March 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Chengdu Easton Biopharmaceuticals' Profit Performance

As we discussed above, we think the significant positive unusual item makes Chengdu Easton Biopharmaceuticals' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Chengdu Easton Biopharmaceuticals' underlying earnings power is lower than its statutory profit. Nonetheless, it's still worth noting that its earnings per share have grown at 13% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Chengdu Easton Biopharmaceuticals, you'd also look into what risks it is currently facing. In terms of investment risks, we've identified 2 warning signs with Chengdu Easton Biopharmaceuticals, and understanding these should be part of your investment process.

Today we've zoomed in on a single data point to better understand the nature of Chengdu Easton Biopharmaceuticals' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.